Skip to main content

toppbild-press-1551x278.jpg

Press

Interview with CEO Anna Ljung

Link to video »

All pressreleases
Regulatory

2020-01-14 | Press release

The Swedish Tax Agency has published a notification on distribution of the acquisition cost of shares due to the redemption in 2019 of shares in Moberg Pharma AB for cash

2019-12-12 | Press release

Moberg Pharma comments on the results of the North American Phase 3 study with MOB-015

2019-12-09 | Press release

Moberg Pharma meets primary endpoint for MOB-015 in a Phase 3 study for the treatment of onychomycosis

2020-01-14 | Press release

The Swedish Tax Agency has published a notification on distribution of the acquisition cost of shares due to the redemption in 2019 of shares in Moberg Pharma AB for cash

2019-12-12 | Press release

Moberg Pharma comments on the results of the North American Phase 3 study with MOB-015

2019-12-09 | Press release

Moberg Pharma meets primary endpoint for MOB-015 in a Phase 3 study for the treatment of onychomycosis

Read more press releases »

Latest report

2019-11-19 Moberg Pharma AB Interim report July - September 2019

Contact for press och media:

Anna Ljung, CEO
Phone: +46 8 522 307 08
Email: anna.ljung@mobergpharma.se

Subscribe

Calendar/presentations

Next calendar event: 2020-02-11 Interim report for July - December 2019